AMLX Stock Price, Amylyx Pharmaceuticals, . Quote, Chart

Market Summary

USD1.830.00

Delayed

0.00%

AMLX Alerts

Big fall in earnings (Y/Y)

Losses in recent quarter

AMLX Stock Price

View Fullscreen

AMLX RSI Chart

AMLX Valuation

Market Cap

124.5M

Price/Earnings (Trailing)

-1.75

Price/Sales (Trailing)

0.31

EV/EBITDA

0.71

Price/Free Cashflow

8.06

AMLX Price/Sales (Trailing)

AMLX Profitability

EBT Margin

-16.50%

Return on Equity

-21.91%

Return on Assets

-17.03%

Free Cashflow Yield

12.41%

AMLX Fundamentals

AMLX Revenue

Revenue (TTM)

398.0M

Rev. Growth (Yr)

24.1%

Rev. Growth (Qtr)

-18.26%

AMLX Earnings

Earnings (TTM)

-71.1M

Earnings Growth (Yr)

-7.7K%

Earnings Growth (Qtr)

-2.6K%

Breaking Down AMLX Revenue

Last 7 days

4.6%

Last 30 days

-8.5%

Last 90 days

-88.5%

Trailing 12 Months

-93.2%

How does AMLX drawdown profile look like?

AMLX Financial Health

Current Ratio

4.48

AMLX Investor Care

Shares Dilution (1Y)

1.24%

Diluted EPS (TTM)

-1.07

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	398.0M	0	0	0
2023	111.9M	201.5M	291.1M	380.8M
2022	0	0	11.3M	22.2M
2021	0	0	0	285.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Amylyx Pharmaceuticals, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 16, 2024	cohen joshua b	acquired	-	-	179,850	co-chief executive officer
Apr 16, 2024	klee justin b.	acquired	-	-	179,850	co-chief executive officer
Apr 16, 2024	bedrosian camille l	acquired	-	-	96,910	chief medical officer
Apr 16, 2024	frates james m	acquired	-	-	91,180	chief financial officer
Apr 16, 2024	mazzariello gina	acquired	-	-	80,560	chief legal officer
Mar 05, 2024	klee justin b.	sold	-77,439	18.7279	-4,135	co-chief executive officer
Mar 05, 2024	mazzariello gina	sold	-28,841	18.7279	-1,540	chief legal officer
Mar 05, 2024	frates james m	sold	-33,560	18.7279	-1,792	chief financial officer
Mar 05, 2024	cohen joshua b	sold	-77,439	18.7279	-4,135	co-chief executive officer
Feb 26, 2024	mazzariello gina	acquired	-	-	36,667	chief legal officer

Which funds bought or sold AMLX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	Beacon Capital Management, LLC	new	-	838	838	-%
May 16, 2024	JANE STREET GROUP, LLC	reduced	-84.61	-1,119,630	218,493	-%
May 16, 2024	JANE STREET GROUP, LLC	added	62.69	449,795	1,430,930	-%
May 16, 2024	JANE STREET GROUP, LLC	sold off	-100	-285,787	-	-%
May 16, 2024	Clear Point Advisors Inc.	new	-	68,916	68,916	0.06%
May 16, 2024	Clear Point Advisors Inc.	added	9.09	80.00	420	-%
May 16, 2024	JANE STREET GROUP, LLC	added	30.42	84,304	366,118	-%
May 16, 2024	COMERICA BANK	new	-	259,517	259,517	-%
May 16, 2024	Tidal Investments LLC	reduced	-4.71	22,390	1,582,110	0.03%
May 16, 2024	Arete Wealth Advisors, LLC	new	-	512,361	512,361	0.05%

Are Funds Buying or Selling AMLX?

Are funds buying AMLX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own AMLX

No. of Funds

Unveiling Amylyx Pharmaceuticals, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 11, 2024	panacea innovation ltd	6.2%	4,200,000	SC 13G
Feb 14, 2024	point72 asset management, l.p.	4.1%	2,751,305	SC 13G/A
Feb 14, 2024	perceptive advisors llc	2.8%	1,869,125	SC 13G/A
Feb 14, 2024	viking global investors lp	4.4%	2,962,555	SC 13G/A
Feb 13, 2024	vanguard group inc	7.81%	5,275,566	SC 13G/A
Jan 29, 2024	blackrock inc.	5.9%	4,002,334	SC 13G
Dec 11, 2023	point72 asset management, l.p.	4.7%	3,176,105	SC 13G
Oct 04, 2023	morningside venture investments ltd	3.43%	2,313,227	SC 13D/A
Aug 17, 2023	morningside venture investments ltd	6.86%	4,618,846	SC 13D/A
Jun 09, 2023	goldman sachs group inc	5.4%	3,653,782	SC 13G

Recent SEC filings of Amylyx Pharmaceuticals, Inc.

View All Filings

Date Filed	Form Type	Document
May 16, 2024	4	Insider Trading
May 16, 2024	4	Insider Trading
May 15, 2024	144	Notice of Insider Sale Intent
May 09, 2024	10-Q	Quarterly Report
May 09, 2024	8-K	Current Report
Apr 24, 2024	ARS	ARS
Apr 24, 2024	DEF 14A	DEF 14A
Apr 24, 2024	DEFA14A	DEFA14A
Apr 18, 2024	4	Insider Trading
Apr 18, 2024	4	Insider Trading

Peers (Alternatives to Amylyx Pharmaceuticals, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Amylyx Pharmaceuticals, Inc. News

Latest updates

Amylyx Pharmaceuticals, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2021Q4	2021Q3
Revenue	-18.3%	88,643,000	108,449,000	102,693,000	98,216,000	71,428,000	53,642,250	35,856,500	18,070,750	285,000
Costs and Expenses	97.9%	210,773,000	106,515,000	83,973,000	78,015,000	73,481,000	66,478,000	55,026,000	-	23,203,000
S&GA Expenses	10.6%	57,759,000	52,241,000	48,718,000	43,391,000	44,006,000	40,844,000	29,940,000	14,921,000	10,350,000
R&D Expenses	-18.5%	36,608,000	44,914,000	30,037,000	29,044,000	24,192,000	22,813,000	24,914,000	13,394,000	12,853,000
EBITDA Margin	-211.5%	-0.16	0.15	0.02	-0.35	-1.32	-8.87	-16.30	-308	-
Income Taxes	-86.4%	242,000	1,776,500	1,518,000	1,900,000	-200,000	553,500	-100,000	-	-
Earnings Before Taxes	-1930.6%	-118,551,000	6,476,000	22,411,000	24,007,000	1,403,000	-42,125,000	-53,881,000	-28,344,000	-23,142,000
EBT Margin	-215.7%	-0.16	0.14	0.02	-0.35	-1.33	-8.89	-16.33	-308	-
Net Income	-2610.9%	-118,793,000	4,731,000	20,893,000	22,074,000	1,573,000	-42,704,000	-53,756,000	-28,344,000	-23,142,000
Net Income Margin	-238.1%	-0.18	0.13	0.01	-0.36	-1.33	-8.92	-16.35	-308	-
Free Cashflow	-104.2%	-556,000	13,195,000	-5,526,000	8,331,000	-5,322,000	-50,317,000	-43,537,000	-28,430,000	-21,018,000

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet										(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Assets	-19.3%	417	517	467	454	408	391	181	225	274	106
Current Assets	-11.6%	411	465	434	427	389	382	172	216	265	105
Cash Equivalents	0.2%	171	170	135	248	115	63.00	108	67.00	110	50.00
Inventory	-100.0%	-	38.00	32.00	25.00	13.00	10.00	1.00	-	-	-
Net PPE	-8.5%	2.00	3.00	3.00	3.00	3.00	3.00	2.00	2.00	1.00	0.00
Liabilities	10.7%	93.00	84.00	48.00	67.00	55.00	51.00	37.00	32.00	33.00	17.00
Current Liabilities	11.7%	92.00	82.00	46.00	64.00	52.00	47.00	33.00	27.00	28.00	17.00
Shareholder's Equity	-25.1%	324	433	418	386	353	341	144	193	241	-
Retained Earnings	-39.0%	-423	-304	-309	-330	-352	-354	-311	-257	-203	-155
Additional Paid-In Capital	1.4%	748	738	728	717	705	695	456	451	445	5.00
Shares Outstanding	0.4%	68.00	68.00	68.00	67.00	67.00	67.00	59.00	58.00	52.00	7.00
Float	-	-	-	-	1,310	-	-	-	788	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)													(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1
Cashflow From Operations	-103.6%	-489	13,551	-5,169	8,609	-5,072	-49,697	-43,078	-46,462	-40,634	-28,244	-20,865	-13,047	-12,643
Share Based Compensation	4.1%	9,924	9,534	10,176	9,950	7,501	6,091	5,524	5,707	4,392	1,091	802	657	586
Cashflow From Investing	-96.1%	819	20,925	-108,088	123,222	55,994	-228,180	84,041	4,462	-99,311	2,814	-49,206	-	-14.00
Cashflow From Financing	-43.0%	131	230	889	1,384	1,040	232,162	-	-828	200,455	-1,065	131,651	1,993	25,927

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

AMLX Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Product revenue, net	$ 88,643	$ 71,428
Revenue from Contract with Customer, Product and Service [Extensible Enumeration]	us-gaap:ProductMember	us-gaap:ProductMember
Operating expenses:
Cost of sales	$ 5,945	$ 5,283
Cost of sales - inventory impairment and loss on firm purchase commitments	110,461
Research and development	36,608	24,192
Selling, general and administrative	57,759	44,006
Total operating expenses	210,773	73,481
Loss from operations	(122,130)	(2,053)
Other income, net:
Interest income	4,326	3,718
Other expense, net	(747)	(262)
Total other income, net	3,579	3,456
(Loss) income before income taxes	(118,551)	1,403
Provision (benefit) for income taxes	242	(170)
Net (loss) income	$ (118,793)	$ 1,573
Net (loss) income per share - basic	$ (1.75)	$ 0.02
Net (loss) income per share - diluted	$ (1.75)	$ 0.02
Weighted-average shares used in computing net (loss) income per share-basic	67,854,356	66,717,271
Weighted-average shares used in computing net (loss) income per share-diluted	67,854,356	70,863,665

AMLX Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 170,552	$ 170,201
Short-term investments	202,741	201,161
Accounts receivable, net	20,351	40,050
Inventories		38,323
Prepaid expenses and other current assets	16,890	14,931
Total current assets	410,534	464,666
Property and equipment, net	2,459	2,686
Restricted cash equivalents	719	719
Operating lease right-of-use assets	3,252	3,725
Long-term inventories		44,957
Other assets	493	701
Total assets	417,457	517,454
Current liabilities:
Accounts payable	21,453	22,061
Accrued expenses	67,874	57,724
Operating lease liabilities, current portion	2,312	2,257
Total current liabilities	91,639	82,042
Operating lease liabilities, net of current portion	1,382	1,980
Total liabilities	93,021	84,022
Commitments and contingencies (Note 11)
Stockholders' equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized
Common stock, $0.0001 par value; 300,000,000 shares authorized; 67,975,587 and 67,707,432 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	7	7
Additional paid-in capital	748,248	738,177
Accumulated deficit	(423,742)	(304,949)
Accumulated other comprehensive (loss) income	(77)	197
Total stockholders' equity	324,436	433,432
Total liabilities and stockholders' equity	$ 417,457	$ 517,454

About Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

CEO	Mr. Joshua B. Cohen
WEBSITE	https://amylyx.com
INDUSTRY	Biotechnology
EMPLOYEES	338

Amylyx Pharmaceuticals, Inc. Frequently Asked Questions

What is the ticker symbol for Amylyx Pharmaceuticals, Inc.? What does AMLX stand for in stocks?

AMLX is the stock ticker symbol of Amylyx Pharmaceuticals, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Amylyx Pharmaceuticals, Inc. (AMLX)?

As of Fri May 17 2024, market cap of Amylyx Pharmaceuticals, Inc. is 124.45 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AMLX stock?

You can check AMLX's fair value in chart for subscribers.

What is the fair value of AMLX stock?

You can check AMLX's fair value in chart for subscribers. The fair value of Amylyx Pharmaceuticals, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Amylyx Pharmaceuticals, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AMLX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Amylyx Pharmaceuticals, Inc. a good stock to buy?

The fair value guage provides a quick view whether AMLX is over valued or under valued. Whether Amylyx Pharmaceuticals, Inc. is cheap or expensive depends on the assumptions which impact Amylyx Pharmaceuticals, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AMLX.

What is Amylyx Pharmaceuticals, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, AMLX's PE ratio (Price to Earnings) is -1.75 and Price to Sales (PS) ratio is 0.31. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AMLX PE ratio will change depending on the future growth rate expectations of investors.